News

The Phase III trial is an open label study in which adult patients with CAH, currently treated with a single or combination of generic steroids (standard-of-care), are randomised

Under the terms of the agreement, Horizon has licensed to the Partner a novel cell line engineering technology as well as non-exclusive rights to Horizon's proprietary Helitron transposon

The approval from the US Food and Drug Administration (FDA) is for CF patients having two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator

This partnership enables Roivant to add an innovative late-stage development program to its pipeline and Poxel gains a strategic development and licensing agreement for imeglimin beyond the company’s

The collaboration and license agreement will see both companies evaluate novel bispecific immuno-oncology agents that combine Pieris’ anticalin technology with select Seattle Genetics cancer-targeted antibodies. The companies will

Ozempic is a new once-weekly analogue of human glucagon-like peptide-1 (GLP-1) indicated as monotherapy when metformin is considered inappropriate due to intolerance or is contraindicated, and as an

The placebo-controlled trial was held in over 1,200 men with nonmetastatic, castration-resistant prostate cancer, who were at high risk for the development of metastasis in spite of being

Under the terms of the agreement, Haichang will develop a nano-liposomal formulation of RX-0201 using its proprietary QTsome™ technology and conduct certain pre-clinical and clinical activities through completion

The updated label includes Cosentyx data in moderate-to-severe scalp psoriasis – one of the difficult-to-treat forms of the disease, which affects approximately half of all psoriasis patients. The